426 related articles for article (PubMed ID: 19714594)
1. Complete resolution of leukemia cutis with sorafenib in an acute myeloid leukemia patient with FLT3-ITD mutation.
Lee SH; Paietta E; Racevskis J; Wiernik PH
Am J Hematol; 2009 Oct; 84(10):701-2. PubMed ID: 19714594
[No Abstract] [Full Text] [Related]
2. Sorafenib treatment in 13 patients with acute myeloid leukemia and activating FLT3 mutations in combination with chemotherapy or as monotherapy.
Schroeder T; Zohren F; Saure C; Bruns I; Czibere A; Safaian NN; Fenk R; Haas R; Kobbe G
Acta Haematol; 2010; 124(3):153-9. PubMed ID: 20938170
[No Abstract] [Full Text] [Related]
3. Marked bone marrow hypoplasia associated with sorafenib-induced marrow blast clearance in two patients with FLT3-ITD acute myeloid leukemia.
Fesler MJ
Leuk Res; 2011 Mar; 35(3):e21-2. PubMed ID: 21144585
[No Abstract] [Full Text] [Related]
4. Sorafenib (Nexavar) induces molecular remission and regression of extramedullary disease in a patient with FLT3-ITD+ acute myeloid leukemia.
Safaian NN; Czibere A; Bruns I; Fenk R; Reinecke P; Dienst A; Haas R; Kobbe G
Leuk Res; 2009 Feb; 33(2):348-50. PubMed ID: 18573526
[TBL] [Abstract][Full Text] [Related]
5. Secondary resistance to sorafenib in two patients with acute myeloid leukemia (AML) harboring FLT3-ITD mutations.
Scholl S; Spies-Weisshart B; Klink A; Muegge LO; Fricke HJ; Hochhaus A
Ann Hematol; 2011 Apr; 90(4):473-5. PubMed ID: 20652568
[No Abstract] [Full Text] [Related]
6. A case of blast clearance on sorafenib in relapsed FLT3-ITD acute myeloid leukemia: evidence of efficacy continues to mount.
Fesler MJ; Richart JM; Petruska PJ
Leuk Res; 2010 Oct; 34(10):e268-9. PubMed ID: 20417967
[No Abstract] [Full Text] [Related]
7. Sorafenib for refractory FMS-like tyrosine kinase receptor-3 (FLT3/ITD+) acute myeloid leukemia after allogenic stem cell transplantation.
Sorà F; Chiusolo P; Metafuni E; Bellesi S; Giammarco S; Laurenti L; Ausoni G; Zini G; Bayer AJ; Mario B; Leone G; Sica S
Leuk Res; 2011 Mar; 35(3):422-3. PubMed ID: 21093053
[No Abstract] [Full Text] [Related]
8. The successful remission induction by sorafenib and long-term complete remission in a FLT3-ITD-positive patient with a refractory acute erythroid leukemia and abnormal cytogenetics.
Mori M; Sprague J
Leuk Res; 2012 Jan; 36(1):e1-3. PubMed ID: 21996560
[No Abstract] [Full Text] [Related]
9. Use of Sorafenib as an effective treatment in an AML patient carrying a new point mutation affecting the Juxtamembrane domain of FLT3.
Martínez-López J; Castro N; Rueda D; Canal A; Grande C; Ayala R
Br J Haematol; 2012 Aug; 158(4):555-8. PubMed ID: 22686329
[No Abstract] [Full Text] [Related]
10. High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses.
Metzelder SK; Schroeder T; Finck A; Scholl S; Fey M; Götze K; Linn YC; Kröger M; Reiter A; Salih HR; Heinicke T; Stuhlmann R; Müller L; Giagounidis A; Meyer RG; Brugger W; Vöhringer M; Dreger P; Mori M; Basara N; Schäfer-Eckart K; Schultheis B; Baldus C; Neubauer A; Burchert A
Leukemia; 2012 Nov; 26(11):2353-9. PubMed ID: 22504140
[TBL] [Abstract][Full Text] [Related]
11. Sorafenib induces sustained molecular remission in FLT3-ITD positive AML with relapse after second allogeneic stem cell transplantation without exacerbation of acute GVHD: a case report.
Winkler J; Rech D; Kallert S; Rech J; Meidenbauer N; Roesler W; Mackensen A
Leuk Res; 2010 Oct; 34(10):e270-2. PubMed ID: 20627386
[No Abstract] [Full Text] [Related]
12. Sorafenib treatment of FLT3-ITD(+) acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation.
Man CH; Fung TK; Ho C; Han HH; Chow HC; Ma AC; Choi WW; Lok S; Cheung AM; Eaves C; Kwong YL; Leung AY
Blood; 2012 May; 119(22):5133-43. PubMed ID: 22368270
[TBL] [Abstract][Full Text] [Related]
13. Aberrant expression of CD7 in myeloblasts is highly associated with de novo acute myeloid leukemias with FLT3/ITD mutation.
Rausei-Mills V; Chang KL; Gaal KK; Weiss LM; Huang Q
Am J Clin Pathol; 2008 Apr; 129(4):624-9. PubMed ID: 18343790
[TBL] [Abstract][Full Text] [Related]
14. Treatment of FLT3-ITD-positive acute myeloid leukemia relapsing after allogeneic stem cell transplantation with sorafenib.
Sharma M; Ravandi F; Bayraktar UD; Chiattone A; Bashir Q; Giralt S; Chen J; Qazilbash M; Kebriaei P; Konopleva M; Andreeff M; Cortes J; McCue D; Kantarjian H; Champlin RE; de Lima M
Biol Blood Marrow Transplant; 2011 Dec; 17(12):1874-7. PubMed ID: 21767516
[TBL] [Abstract][Full Text] [Related]
15. Antitumor activity of sorafenib in FLT3-driven leukemic cells.
Auclair D; Miller D; Yatsula V; Pickett W; Carter C; Chang Y; Zhang X; Wilkie D; Burd A; Shi H; Rocks S; Gedrich R; Abriola L; Vasavada H; Lynch M; Dumas J; Trail PA; Wilhelm SM
Leukemia; 2007 Mar; 21(3):439-45. PubMed ID: 17205056
[TBL] [Abstract][Full Text] [Related]
16. Sorafenib monotherapy gives sustainable suppression of FLT3 clone in untreated patients with FLT3-internal tandem duplication positive acute myeloid Leukaemia.
Mohan BP; How GF; Loh Y; Linn YC
Br J Haematol; 2012 Apr; 157(1):131-2. PubMed ID: 22050655
[No Abstract] [Full Text] [Related]
17. A rapid, one step assay for simultaneous detection of FLT3/ITD and NPM1 mutations in AML with normal cytogenetics.
Huang Q; Chen W; Gaal KK; Slovak ML; Stein A; Weiss LM
Br J Haematol; 2008 Jul; 142(3):489-92. PubMed ID: 18477048
[No Abstract] [Full Text] [Related]
18. Low frequency and variability of FLT3 mutations in Korean patients with acute myeloid leukemia.
Bang SM; Ahn JY; Park J; Park SH; Park J; Cho EK; Shin DB; Lee JH; Yoo SJ; Jeon IS; Kim YK; Kim HJ; Kim HN; Lee IK; Kang HJ; Shin HY; Ahn HS
J Korean Med Sci; 2008 Oct; 23(5):833-7. PubMed ID: 18955790
[TBL] [Abstract][Full Text] [Related]
19. FLT3 inhibitors for the treatment of acute myeloid leukemia.
Wiernik PH
Clin Adv Hematol Oncol; 2010 Jun; 8(6):429-36, 444. PubMed ID: 20733555
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of foetal-like tyrosine kinase 3 mutation in Egyptian children with acute leukaemia.
Al-Tonbary Y; Mansour AK; Ghazy H; Elghannam DM; Abd-Elghaffar HA
Int J Lab Hematol; 2009 Jun; 31(3):320-6. PubMed ID: 18336585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
